FO
PBYI icon

FT Options’s Puma Biotechnology PBYI Stock Holding History

FT Options’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$1.37M Buy
+11,438
New +$1.06M 2.06% 11
2017
Q2 		– Sell
-6,039
Closed -$338K – 258
2017
Q1 		$225K Buy
+6,039
New +$220K 0.3% 73
2016
Q4 		– Sell
-21,338
Closed -$1.43M – 346
2016
Q3 		$1.43M Buy
+21,338
New +$1.08M 1.13% 21

Other funds holding PBYI

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

FT Options's PBYI Position: Q3 2017 in Review

FT Options opened a new position in Puma Biotechnology (PBYI) in Q3 2017: 11,438 shares worth $1.37M. The stake represents 2.06% of the portfolio and ranks #11 among its holdings. This is a return to the name: FT Options previously reported a position in PBYI as recently as Q1 2017.

FT Options first reported a position in PBYI in Q3 2016 and has held it in 3 quarters since. The position peaked at $1.43M in Q3 2016. 171 funds tracked by Wall St. Rank hold PBYI as of Q3 2017.

  • FT Options held 11,438 shares of Puma Biotechnology worth $1.37M as of Q3 2017.
  • Puma Biotechnology was a new FT Options position in Q3 2017.
  • Puma Biotechnology made up 2.06% of FT Options's portfolio in Q3 2017, its #11 holding.
  • FT Options first reported a position in Puma Biotechnology in Q3 2016 and has held it in 3 quarters since.
  • FT Options's Puma Biotechnology position peaked at $1.43M in Q3 2016.
  • 171 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2017.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.